New mRNA flu shot shows promise in early trial
NCT ID NCT05606965
First seen Jan 04, 2026 · Last updated Apr 29, 2026 · Updated 18 times
Summary
This study tested a new mRNA-based flu vaccine (mRNA-1010) in 172 healthy adults aged 18-50 and 65-80. The goal was to check its safety and how well it boosts the immune system compared to standard flu vaccines. Results help determine if the vaccine is safe and produces a strong antibody response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Washington University in St. Louis
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.